Compare CPSH & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPSH | MXCT |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 81.6M |
| IPO Year | 1995 | 2021 |
| Metric | CPSH | MXCT |
|---|---|---|
| Price | $3.62 | $0.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $6.00 | $5.50 |
| AVG Volume (30 Days) | 150.9K | ★ 985.7K |
| Earning Date | 03-02-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.64 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | $16.41 | $18.61 |
| Revenue Next Year | $20.16 | $22.36 |
| P/E Ratio | $126.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.40 | $0.64 |
| 52 Week High | $6.85 | $2.96 |
| Indicator | CPSH | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 34.31 |
| Support Level | $3.61 | $0.64 |
| Resistance Level | $4.41 | $0.87 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 20.55 | 9.08 |
CPS Technologies Corp designs, manufactures, and sells high-performance material solutions for customers across various markets, including transportation, energy, automotive, electronics, telecommunications, aerospace, and defense. The company develops and applies proprietary expertise in metal matrix composites (MMCs), which are engineered materials combining metals and ceramics to achieve enhanced performance properties. It also provides baseplates and housings used in radar, satellite and avionics applications. The company provides lids and heat spreaders used with integrated circuits in Internet switches and routers. The majority of the company's revenue is derived from the sale of its products in the United States of America.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.